AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06064123 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cell-free DNA
Description: Donor-derived cell-free DNA relation to recipient-derived cell-free DNA is compared to histopathological rejection grade from the same time frame.
Study NCT04604795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Description: Placebo matching GSK3915393 capsules will be given orally.
Study NCT05002842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LovingKindess Meditation
Description: Participants will have access to a recording of a script to guide them through meditation
Study NCT04430647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined phacoemulsification and ultrasound ciliary plasty (Phaco-UCP)
Description: performing ultrasound ciliary plasty then performing standard phacoemulsification
Study NCT04430647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification alone
Description: standard phacoemulsification for catarct extraction
Study NCT00041119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC regimen
Description: Given IV
Study NCT00041119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC regimen
Description: Given IV
Study NCT02563795 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine
Description: To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
Study NCT02563795 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Description: To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
Study NCT00238121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT01092533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
Study NCT04604795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo matching GSK3915393 capsules will be given orally.
Study NCT04604795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will be administered with GSK3915393 along with ITZ orally
Study NCT04604795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will be administered with GSK3915393 along with water orally
Study NCT04604795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape fruit juice
Description: Participants will be administered with GSK3915393 along with GFJ orally
Study NCT02523261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct aspiration procedure
Description: Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
Study NCT02523261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stent retriever procedure
Description: Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
Study NCT02653833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 MG
Description: Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
Study NCT02653833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: beetroot juice extract
Description: Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
Study NCT06400030 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Root canal treatment with AH Plus sealer
Description: - AH Plus sealer Group: the base and accelerator of AH Plus Sealer was mixed, then the walls of the canal were coated with the AH Plus sealer using K-File, then lateral condensation was performed through a number of gutta-percha cones.
Study NCT06400030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment with BioCeramic sealer
Description: - BioCeramic Sealer Group: the canals in this group were filled using BioCeramic-based sealer and a single gutta-percha cone, and gently insert it into the root canal to the preselected working length without applying pressure.
Study NCT01092533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decortin
Description: Maintenance dose 5 mg/d
Study NCT01092533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decortin
Description: Maintenance dose 5 mg/d
Study NCT03016923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Therapy
Description: FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
Study NCT03274804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
Study NCT03274804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
Study NCT02583321 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tubes not allowing SSD
Description: In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
Study NCT02583321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tubes allowing SSD
Description: In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.
Study NCT01742507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity Stent
Description: Resolute Integrity Stent
Study NCT01742507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biomatrix stent
Description: Biomatrix stent
Study NCT01733433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taping the ankle
Description: Subjects will be taped in at the ankle for performing several exercises.
Study NCT02411786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-AR
Description: Given ID
Study NCT02541747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: massage
Study NCT05190731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic cranial manipulative medicine
Description: Osteopathic cranial manipulative medicine technique using compression of 4th ventricle technique
Study NCT02411786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gm-csf
Description: Given ID
Study NCT01531972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-228432
Description: 40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
Study NCT01531972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-228432
Description: 40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
Study NCT03055390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butylbromide
Description: Intravenous administration of hyoscine butylbromide during first stage of labor
Study NCT00538369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ramsay Scale
Description: While receiving sedation, subjects will be monitored with the Ramsay scale
Study NCT05190731 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Touch only, no osteopathic cranial manipulation
Study NCT03055390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2ml of saline intravenous
Study NCT03762967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipoaspiration and SVF introduction.
Description: Lipoaspiration, isolation of SVF and introduction into testis Interstitium.
Study NCT03762967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy.
Description: Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
Study NCT03762967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy.
Description: Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
Study NCT03128190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse pressure variation monitoring
Description: fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
Study NCT02228096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019 T-cells
Description: A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10\^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients > 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10\^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10\^8 CTL019 transduced viable T cells (for patients > 50 kg).
Study NCT01969721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: low dose
Study NCT01969721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Study NCT00041119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00041119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00041119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00041119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01969721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo/dummy for blinding purposes
Study NCT01969721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo/dummy for blinding purposes
Study NCT01969721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: tiotropium high dose
Study NCT01969721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Study NCT01969721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: tiotropium low dose
Study NCT00512291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
Study NCT00640367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alteplase IA and/or mechanical thrombolysis
Description: loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
Study NCT00640367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase IV
Description: intravenous recombinant tissue plasminogen activator
Study NCT01977690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clavicle Brace
Study NCT04276974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organic diet
Description: Organic plant-rich foods (2000kcal for women, 2500kcal for men)
Study NCT04276974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-organic diet
Description: Likewise Non-organic plant-rich foods (2000kcal for women, 2500kcal for men)
Study NCT00538369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ramsay Scale
Description: While receiving sedation, subjects will be monitored with the Ramsay scale
Study NCT00538369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index monitor
Description: While receiving sedation, subjects will receive BIS monitoring
Study NCT01861912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arsenic trioxide TACE
Description: Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities
Study NCT01861912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide TACE
Description: Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4\~6 weeks if it is necessary according to the assessment from imaging modalities
Study NCT01861912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide intravenous infusion
Description: Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7\~14 days after TACE.
Study NCT01861912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipiodol
Description: Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
Study NCT01861912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipiodol
Description: Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
Study NCT01861912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl solution
Description: 250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
Study NCT02498041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transnasal Endoscopy
Description: Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
Study NCT02498041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Office-based disposable transnasal endoscopy Endosheath
Description: Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
Study NCT02498041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard upper GI endoscopy
Description: Upper GI endoscopy with standard gastroscope.
Study NCT02498041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal biopsies
Description: 2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
Study NCT02498041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal biopsies
Description: 2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
Study NCT03166072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-vision rehabilitation program
Description: Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
Study NCT03166072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention
Description: Participants will continue to receive treatment as usual
Study NCT04402541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5339
Description: 25mg and 75mg capsules
Study NCT00086645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram hydrobromide
Description: 10mg/5ml solution
Study NCT00086645 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: up to equivalent of 20 mg of active comparator daily
Study NCT03423524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropure 1.2.3.
Description: Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted
Study NCT04453176 — intervention group
Intervention type: OTHER
Intervention: Patient Satisfaction
Description: Patient satisfaction evaluated with EVAN G questionnaire
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Paclitaxel + Carboplatin (Cohort 1)
Description: Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel \[200 milligram/square meter (mg/m\^2)\] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram\*minute/milliliter (mg\*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Paclitaxel + Carboplatin (Cohort 2)
Description: Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Paclitaxel + Carboplatin (Cohort 3)
Description: Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m\^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Paclitaxel (Cohort 4)
Description: Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m\^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Docetaxel + Carboplatin (Cohort 4a)
Description: Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m\^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg\*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Docetaxel (Cohort 5)
Description: Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m\^2) 60-minute infusion on Day 1 of each cycle.
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Capecitabine (Cohort 6)
Description: Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Capecitabine (Cohort 7)
Description: Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m\^2) orally BID from Day 1 to Day 14 of each cycle.
Study NCT00454649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib + Gemcitabine + Cisplatin (Cohort 8)
Description: Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m\^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m\^2) infusion on Day 1 of each cycle.